Alembic Pharma gains 4% on USFDA nod for key diabetes drug
Alembic Pharma gets USFDA nod for generic Dapagliflozin tablets, equivalent to AstraZenecas Farxiga, gaining 180 day shared exclusivity in a $10.49 billion US market
admin
Nykaa shares fall even after strong Q4 update; Street divided on whether stock can rally
Brokerages expect Nykaa to deliver strong Q4 growth led by beauty and improving traction in fashion, with margins set to expand and losses narrowing, though views remain divided on valuations.
Manish Sonthalia flags 12–13% earnings reset as global shock clouds FY27 outlook
Manish Sonthalia, CIO of Emkay Investment Managers highlights opportunities in financials, defence, power and IT, while advising caution on travel and real estate amid cost pressures.
CreditAccess Grameen shares gain up to 10% but cool off on strong Q4 update, normal asset quality
CreditAccess Grameen reported strong growth with higher disbursements, improvement in asset quality and branch expansion for the financial year 2026.
Jan–March FY26 earnings growth lowered to 10%; mid and small-caps under pressure
Gautam Duggad, Head of Research, Director – Institutional Equities at Motilal Oswal Financial Services noted that sectoral trends have led to a broader earnings downgrade of around 3% across his coverage universe of over 360 stocks. Within this, midcaps and…
A great earnings season is likely around the corner. Will it matter to the market?
Wall Street expects strong Q1 earnings led by tech despite US Iran war, oil price surge and valuations pose risks, energy profits may rise, investors hope conflict eases soon
Buzzing Stocks: Railway company jumps 12%, most in a year; Here are the key triggers
Brokerage firm Jefferies expects this railway stock to be a key beneficiary of the increasing passenger and metro coach demand. The stock has corrected significantly from record high levels.
Rupee edges higher against dollar amid RBI support; oil risks cap gains
Rupee opens at 93 per dollar after RBI backed unwinding, stabilising from recent volatility, but remains vulnerable as Iran tensions lift Brent crude to about 111 per barrel
BoFA downgrades these two PSU Banks on asset quality risks; SBI upgraded
BofA said the recent correction in banking stocks appears overdone, with value emerging, particularly in large banks. It has turned more constructive on the segment, citing the current macro outlook and attractive valuations.
Buy the Giants, Avoid the Rest? BoFA bets on two large banks, downgrades popular smaller ones
HDFC Bank’s revised price target implies an upside potential of 24% from current levels, while for ICICI Bank, the revised price target indicates a 22% potential upside.